Real-Time Use of SGLT2i Verified in Pre-dialysis: The RSVP Cross-sectional Study.

Aylon WisbaumSandrine GaudreauIsabelle CloutierPascale RobertRegina KolmentMarie-France BeauchesneJodianne Couture

Published in: The Annals of pharmacotherapy (2024)

An increasing number of patients with CKD are being prescribed SGLT2i. Nonetheless, significant disparities in sex, severity of disease, and comorbidities remain. We suggest that specific strategies be put in place to promote prescribing of SGLT2i in women and other at-risk populations, in particular among nephrology teams, to improve patient care.

Keyphrases

chronic kidney disease
primary care
end stage renal disease
polycystic ovary syndrome
pregnancy outcomes
healthcare
type diabetes
emergency department
pregnant women
insulin resistance
genetic diversity
health insurance